Clinical Trials
3
Active:0
Completed:3
Trial Phases
1 Phases
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (100.0%)Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)
Phase 2
Completed
- Conditions
- Chronic DiarrheaBile Acid DiarrheaIrritable Bowel Syndrome With DiarrheaBile Acid MalabsorptionFunctional DiarrheaBile Acid Malabsorption Syndrome Type II
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Michael Camilleri, MD
- Target Recruit Count
- 30
- Registration Number
- NCT05130047
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Michael Camilleri, MD
- Target Recruit Count
- 136
- Registration Number
- NCT03523273
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Effect of Ileal Bile Acid Transporter Inhibitor in Functional Constipation
- First Posted Date
- 2009-12-24
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- Michael Camilleri, MD
- Target Recruit Count
- 36
- Registration Number
- NCT01038687
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
News
No news found